HP and hepatocellular carcinoma: For example, fucosylated haptoglobin correlates with poorer survival probability, reduced responsiveness to therapy, and increased metastatic burden in breast [31], HCC [69,70,71], ovarian [31,55,72], CRC [67], pancreatic [73], and lung [31,74] cancer patients.